{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:57:27Z","timestamp":1786982247481,"version":"build-2736575974"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T00:00:00Z","timestamp":1629504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T00:00:00Z","timestamp":1629504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s12072-021-10247-x","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T20:03:00Z","timestamp":1629489780000},"page":"1196-1206","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["A network meta-analysis of direct oral anticoagulants for portal vein thrombosis in cirrhosis"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8297-1569","authenticated-orcid":false,"given":"Cheng Han","family":"Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren Jun Hao","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kameswara Rishi Yeshayahu","family":"Nistala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Syn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieling","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice Xiang Xuan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia Zuying","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas W. S.","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Q.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yock Young","family":"Dan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9724-4743","authenticated-orcid":false,"given":"Mark D.","family":"Muthiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,21]]},"reference":[{"issue":"3","key":"10247_CR1","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1365-2036.2009.04182.x","volume":"31","author":"EA Tsochatzis","year":"2010","unstructured":"Tsochatzis EA, Senzolo M, Germani G, Gatt A, Burroughs AK. Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther 2010;31(3):366\u2013374","journal-title":"Aliment Pharmacol Ther"},{"key":"10247_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31646","author":"PG Northup","year":"2020","unstructured":"Northup PG, Garcia-Pagan JC, Garcia-Tsao G, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2020. https:\/\/doi.org\/10.1002\/hep.31646","journal-title":"Hepatology"},{"issue":"1","key":"10247_CR3","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/ajg.2008.34","volume":"104","author":"KK S\u00f8gaard","year":"2009","unstructured":"S\u00f8gaard KK, Horv\u00e1th-Puh\u00f3 E, Gr\u00f8nbaek H, Jepsen P, Vilstrup H, S\u00f8rensen HT. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastroenterol 2009;104(1):96\u2013101","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10247_CR4","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1056\/NEJMra1011170","volume":"365","author":"A Tripodi","year":"2011","unstructured":"Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011;365(2):147\u2013156","journal-title":"N Engl J Med"},{"issue":"5","key":"10247_CR5","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/S1665-2681(19)31312-2","volume":"12","author":"J Muci\u00f1o-Bermejo","year":"2013","unstructured":"Muci\u00f1o-Bermejo J, Carrillo-Esper R, Uribe M, M\u00e9ndez-S\u00e1nchez N. Coagulation abnormalities in the cirrhotic patient. Ann Hepatol 2013;12(5):713\u2013724","journal-title":"Ann Hepatol"},{"issue":"12","key":"10247_CR6","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1161\/01.CIR.0000063575.17904.4E","volume":"107","author":"J Hirsh","year":"2003","unstructured":"Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association\/American College of Cardiology foundation guide to Warfarin therapy. Circulation 2003;107(12):1692\u20131711","journal-title":"Circulation"},{"issue":"3","key":"10247_CR7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jmv.2014.03.001","volume":"39","author":"MA Sevestre","year":"2014","unstructured":"Sevestre MA, Belizna C, Durant C, et al. Compliance with recommendations of clinical practice in the management of venous thromboembolism in cancer: the CARMEN study. J Mal Vasc 2014;39(3):161\u2013168","journal-title":"J Mal Vasc"},{"key":"10247_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2019-000284","author":"Z Marchocki","year":"2019","unstructured":"Marchocki Z, Norris L, Toole S, Gleeson N, Saadeh FA. Patients\u2019 experience and compliance with extended low molecular weight heparin prophylaxis post-surgery for gynecological cancer: a prospective observational study. Int J Gynecol Cancer 2019. https:\/\/doi.org\/10.1136\/ijgc-2019-000284","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"10247_CR9","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1161\/ATVBAHA.115.303397","volume":"35","author":"H Yeh Calvin","year":"2015","unstructured":"Yeh Calvin H, Hogg K, Weitz JI. Overview of the new oral anticoagulants. Arterioscler Thromb Vasc Biol 2015;35(5):1056\u20131065","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"10247_CR10","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1182\/blood.2020005819","volume":"136","author":"FI Mulder","year":"2020","unstructured":"Mulder FI, Bosch FTM, Young AM, et al. Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. Blood 2020;136(12):1433\u20131441","journal-title":"Blood"},{"key":"10247_CR11","doi-asserted-by":"publisher","first-page":"j5058","DOI":"10.1136\/bmj.j5058","volume":"359","author":"JA L\u00f3pez-L\u00f3pez","year":"2017","unstructured":"L\u00f3pez-L\u00f3pez JA, Sterne JAC, Thom HHZ, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ 2017;359:j5058","journal-title":"BMJ"},{"issue":"2","key":"10247_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","volume":"149","author":"C Kearon","year":"2016","unstructured":"Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016;149(2):315\u2013352","journal-title":"Chest"},{"key":"10247_CR13","doi-asserted-by":"publisher","first-page":"8432781","DOI":"10.1155\/2018\/8432781","volume":"2018","author":"P Priyanka","year":"2018","unstructured":"Priyanka P, Kupec JT, Krafft M, Shah NA, Reynolds GJ. Newer oral anticoagulants in the treatment of acute portal vein thrombosis in patients with and without cirrhosis. Int J Hepatol 2018;2018:8432781","journal-title":"Int J Hepatol"},{"issue":"2","key":"10247_CR14","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1055\/s-0039-1679934","volume":"39","author":"EM Weinberg","year":"2019","unstructured":"Weinberg EM, Palecki J, Reddy KR. Direct-acting oral anticoagulants (DOACs) in cirrhosis and cirrhosis-associated portal vein thrombosis. Semin Liver Dis 2019;39(2):195\u2013208","journal-title":"Semin Liver Dis"},{"issue":"2","key":"10247_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40262-012-0030-9","volume":"52","author":"F Scaglione","year":"2013","unstructured":"Scaglione F. New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet 2013;52(2):69\u201382","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10247_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/hepr.12895","volume":"48","author":"YA Nagaoki","year":"2018","unstructured":"Nagaoki YA, Hiroshi A, Daijyo K, Teraoka Y, Shinohara F, Nakamura Y, Hatooka M, Morio K, Nakahara T, Kawaoka T, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Ochi H, Chayama K. Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis. Hepatol Res 2018;48(1):51\u201358","journal-title":"Hepatol Res"},{"key":"10247_CR17","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.vph.2018.05.002","volume":"113","author":"ASA-E Hanafy","year":"2019","unstructured":"Hanafy ASA-E, Sherief A-E, Dawoud MM. Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis. Vasc Pharmacol 2019;113:86\u201391","journal-title":"Vasc Pharmacol"},{"key":"10247_CR18","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1097\/MEG.0000000000001846","volume":"32","author":"MHD Ai","year":"2020","unstructured":"Ai MHD, Wei G, Tan XP, Xu L, Xu C, Zhang Q, Zhang Y, Li J. Efficacy and safety study of direct-acting oral anticoagulants for the treatment of chronic portal vein thrombosis in patients with liver cirrhosis. Eur J Gastroenterol Hepatol 2020;32:1395\u20131400","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10247_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-020-06695-4","author":"LT Naymagon","year":"2020","unstructured":"Naymagon LT, Douglas T, Zubizarreta N, Moshier E, Mascarenhas J, Schiano T. Safety, efficacy, and long-term outcomes of anticoagulation in cirrhotic portal vein thrombosis. Dig Dis Sci 2020. https:\/\/doi.org\/10.1007\/s10620-020-06695-4","journal-title":"Dig Dis Sci"},{"issue":"1","key":"10247_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ejim.2014.12.002","volume":"26","author":"X Qi","year":"2015","unstructured":"Qi X, De Stefano V, Li H, Dai J, Guo X, Fan D. Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. Eur J Intern Med 2015;26(1):23\u201329","journal-title":"Eur J Intern Med"},{"issue":"2","key":"10247_CR21","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1053\/j.gastro.2017.04.042","volume":"153","author":"L Loffredo","year":"2017","unstructured":"Loffredo L, Pastori D, Farcomeni A, Violi F. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis. Gastroenterology 2017;153(2):480-487.e481","journal-title":"Gastroenterology"},{"issue":"5","key":"10247_CR22","first-page":"521","volume":"33","author":"BP Mohan","year":"2020","unstructured":"Mohan BP, Aravamudan VM, Khan SR, Ponnada S, Asokkumar R, Adler DG. Treatment response and bleeding events associated with anticoagulant therapy of portal vein thrombosis in cirrhotic patients: systematic review and meta-analysis. Ann Gastroenterol 2020;33(5):521\u2013527","journal-title":"Ann Gastroenterol"},{"issue":"7","key":"10247_CR23","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6(7):e1000097\u2013e1000097","journal-title":"PLoS Med"},{"issue":"9","key":"10247_CR24","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1111\/jth.14935","volume":"18","author":"S Zuily","year":"2020","unstructured":"Zuily S, Cohen H, Isenberg D, et al. Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2020;18(9):2126\u20132137","journal-title":"J Thromb Haemost"},{"key":"10247_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000010.pub3","author":"S Hopewell","year":"2007","unstructured":"Hopewell S, McDonald S, Clarke MJ, Egger M. Grey literature in meta-analyses of randomized trials of health care interventions. Cochrane Database Systematic Rev 2007. https:\/\/doi.org\/10.1002\/14651858.MR000010.pub3","journal-title":"Cochrane Database Systematic Rev"},{"key":"10247_CR26","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/9781119536604.ch3","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"JE McKenzie","year":"2019","unstructured":"McKenzie JE, Brennan SE, Ryan RE, Thomson HJ, Johnston RV, Thomas J. Defining the Criteria for Including Studies and how they will be Grouped for the Synthesis. In Cochrane Handbook for Systematic Reviews of Interventions. New Jersey: Wiley; 2019. p 33\u201365"},{"issue":"1","key":"10247_CR27","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol 2014;14(1):135","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"10247_CR28","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3(4):692\u2013694","journal-title":"J Thromb Haemost"},{"issue":"11","key":"10247_CR29","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","volume":"13","author":"S Kaatz","year":"2015","unstructured":"Kaatz S, Ahmad D, Spyropoulos AC, Schulman S, Anticoagulation tSoCo. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 2015;13(11):2119\u20132126","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10247_CR30","first-page":"951","volume":"15","author":"IR White","year":"2015","unstructured":"White IR. Network meta-analysis. Stand Genom Sci 2015;15(4):951\u2013985","journal-title":"Stand Genom Sci"},{"issue":"2","key":"10247_CR31","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jrsm.1045","volume":"3","author":"IR White","year":"2012","unstructured":"White IR, Barrett JK, Jackson D, Higgins JPT. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods 2012;3(2):111\u2013125","journal-title":"Res Synth Methods"},{"issue":"1","key":"10247_CR32","doi-asserted-by":"publisher","first-page":"943","DOI":"10.18549\/PharmPract.2017.01.943","volume":"15","author":"FS Tonin","year":"2017","unstructured":"Tonin FS, Rotta I, Mendes AM, Pontarolo R. Network meta-analysis: a technique to gather evidence from direct and indirect comparisons. Pharm Pract (Granada) 2017;15(1):943\u2013943","journal-title":"Pharm Pract (Granada)"},{"key":"10247_CR33","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2017047","volume":"39","author":"SA-O Shim","year":"2017","unstructured":"Shim SA-O, Yoon BA-O, Shin IA-O, Bae JA-O. Network meta-analysis: application and practice using Stata. Epidemiol Health 2017;39: e2017047 (2092-7193 (Electronic))","journal-title":"Epidemiol Health"},{"key":"10247_CR34","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti G, Ades AE, Ioannidis JPA, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011;64:163\u2013171 (1878-5921 (Electronic))","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"10247_CR35","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/jrsm.1348","volume":"10","author":"G Schwarzer","year":"2019","unstructured":"Schwarzer G, Chemaitelly H, Abu-Raddad LJ, R\u00fccker G. Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions. Res Synth Methods 2019;10(3):476\u2013483","journal-title":"Res Synth Methods"},{"key":"10247_CR36","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/hep.31646","volume":"73","author":"PG Northup","year":"2020","unstructured":"Northup PG, Garcia-Pagan JC, Garcia-Tsao G, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2020;73:366\u2013413","journal-title":"Hepatology"},{"key":"10247_CR37","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898","journal-title":"BMJ"},{"issue":"3","key":"10247_CR38","doi-asserted-by":"publisher","first-page":"123","DOI":"10.15171\/ijhpm.2014.71","volume":"3","author":"Z Munn","year":"2014","unstructured":"Munn Z, Moola S, Riitano D, Lisy K. The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence. Int J Health Policy Manag 2014;3(3):123\u2013128","journal-title":"Int J Health Policy Manag"},{"issue":"9","key":"10247_CR39","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000228","volume":"11","author":"TS Zhou","year":"2020","unstructured":"Zhou TS, Xin S, Zhou T, Li Y, Chen X, Cheng B, Gao Y. Efficacy and safety of nadroparin calcium-warfarin sequential anticoagulation in portal vein thrombosis in cirrhotic patients: a randomized controlled trial. Clin Transl Gastroenterol 2020;11(9): e00228","journal-title":"Clin Transl Gastroenterol"},{"issue":"3","key":"10247_CR40","doi-asserted-by":"publisher","first-page":"E107","DOI":"10.1111\/hepr.12934","volume":"48","author":"HK Hidaka","year":"2018","unstructured":"Hidaka HK, Shigehiro K, Sato T, Katsushima S, Izumi N, Igura T, Asahara S, Notsumata K, Osaki Y, Tsuji K, Kawanaka H, Akahoshi T, Hirota S, Matsutani S. Antithrombin III for portal vein thrombosis in patients with liver disease: a randomized, double-blind, controlled trial. Hepatol Res 2018;48(3):E107\u2013E116","journal-title":"Hepatol Res"},{"issue":"4","key":"10247_CR41","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.clinre.2018.11.011","volume":"43","author":"ME-P Berg\u00e8re","year":"2019","unstructured":"Berg\u00e8re ME-P, Domitille E-P, Boillot O, Valette PJ, Guillaud O, Chambon-Augoyard C, Dumortier J. Portal vein thrombosis and liver cirrhosis: Long-term anticoagulation is effective and safe. Clin Res Hepatol Gastroenterol 2019;43(4):395\u2013402","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"4","key":"10247_CR42","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3350\/cmh.2014.20.4.384","volume":"20","author":"JWK Chung","year":"2014","unstructured":"Chung JWK, Gi H, Lee JH, Ok KS, Jang ES, Jeong SH, Kim JW. Safety, efficacy, and response predictors of anticoagulation for the treatment of nonmalignant portal-vein thrombosis in patients with cirrhosis: a propensity score matching analysis. Clin Mol Hepatol 2014;20(4):384\u2013391","journal-title":"Clin Mol Hepatol"},{"key":"10247_CR43","doi-asserted-by":"publisher","first-page":"S171","DOI":"10.1016\/S1590-8658(13)60485-5","volume":"45","author":"GG Caracciolo","year":"2013","unstructured":"Caracciolo GG, Garcovich M, Zocco MA, Ainora ME, Roccarina D, Annicchiarico BE, Ponziani FR, Siciliano M, Gasbarrini A. Clinical outcome of partial portal vein thrombosis in cirrhotic patients: To observe or to treat? Digest Liver Dis 2013;45:S171","journal-title":"Digest Liver Dis"},{"key":"10247_CR44","doi-asserted-by":"publisher","first-page":"265A","DOI":"10.1016\/S0618-8278(19)30501-8","volume":"70","author":"CA Walker","year":"2019","unstructured":"Walker CA, Martens J, Laryea M, Ramaraju GA, Levstik MA, Melaragno J. Evaluation of the efficacy of apixaban use for the treatment of portal vein thrombosis in patients with cirrhosis. Hepatology 2019;70:265A","journal-title":"Hepatology"},{"issue":"4","key":"10247_CR45","first-page":"57","volume":"8","author":"F Almarshad","year":"2018","unstructured":"Almarshad F, Alaklabi A, Bakhsh E, Pathan A, Almegren M. Use of direct oral anticoagulants in daily practice. Am J Blood Res 2018;8(4):57\u201372","journal-title":"Am J Blood Res"},{"issue":"13","key":"10247_CR46","volume":"9","author":"A Chen","year":"2020","unstructured":"Chen A, Stecker E, Bruce AW. Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc 2020;9(13): e017559","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10247_CR47","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s11239-015-1310-7","volume":"41","author":"AE Burnett","year":"2016","unstructured":"Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansell J. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis 2016;41(1):206\u2013232","journal-title":"J Thromb Thrombolysis"},{"issue":"7","key":"10247_CR48","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.cgh.2020.08.007","volume":"19","author":"JF Mort","year":"2021","unstructured":"Mort JF, Davis JPE, Mahoro G, Stotts MJ, Intagliata NM, Northup PG. Rates of bleeding and discontinuation of direct oral anticoagulants in patients with decompensated cirrhosis. Clin Gastroenterol Hepatol 2021;19(7):1436\u20131442","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10247_CR49","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jhep.2021.04.029","volume":"75","author":"M Senzolo","year":"2021","unstructured":"Senzolo M, Garcia-Tsao G, Garc\u00eda-Pag\u00e1n JC. Current knowledge and management of portal vein thrombosis in cirrhosis. J Hepatol 2021;75(2):442\u2013453","journal-title":"J Hepatol"},{"issue":"5","key":"10247_CR50","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1007\/s12325-020-01307-z","volume":"37","author":"S Ballestri","year":"2020","unstructured":"Ballestri S, Capitelli M, Fontana MC, et al. Direct oral anticoagulants in patients with liver disease in the era of non-alcoholic fatty liver disease global epidemic: a narrative review. Adv Ther 2020;37(5):1910\u20131932","journal-title":"Adv Ther"},{"issue":"36","key":"10247_CR51","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000022054","volume":"99","author":"RZ Hern\u00e1ndez","year":"2020","unstructured":"Hern\u00e1ndez RZ, Dalmau LMR, Aguilar MC, et al. Cost-effectiveness of direct oral anticoagulants versus vitamin K antagonist in atrial fibrillation: a study protocol using Real-World Data from Catalonia (FantasTIC Study). Medicine 2020;99(36): e22054","journal-title":"Medicine"},{"issue":"2","key":"10247_CR52","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1080\/14737167.2020.1798233","volume":"21","author":"E Walter","year":"2021","unstructured":"Walter E, Voit M, Eichhober G. Cost-effectiveness analysis of apixaban compared to other direct oral anticoagulants for prevention of stroke in Austrian atrial fibrillation patients. Expert Rev Pharmacoecon Outcomes Res 2021;21(2):265\u2013275","journal-title":"Expert Rev Pharmacoecon Outcomes Res"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-021-10247-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-021-10247-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-021-10247-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T16:26:15Z","timestamp":1634142375000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-021-10247-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,21]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10247"],"URL":"https:\/\/doi.org\/10.1007\/s12072-021-10247-x","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,21]]},"assertion":[{"value":"4 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Arun J. Sanyal: Dr Sanyal is President of Sanyal Biotechnology and has stock options in Genfit, Akarna, Tiziana, Indalo, Durect and Galmed. He has served as a consultant to Astra Zeneca, Nitto Denko, Enyo, Ardelyx, Conatus, Nimbus, Amarin, Salix, Tobira, Takeda, Jannsen, Gilead, Terns, Birdrock, Merck, Valeant, Boehringer\u2010Ingelheim, Lilly, Hemoshear, Zafgen, Novartis, Novo Nordisk, Pfizer, Exhalenz and Genfit. He has been an unpaid consultant to Intercept, Echosens, Immuron, Galectin, Fractyl, Syntlogic, Affimune, Chemomab, Zydus, Nordic Bioscience, Albireo, Prosciento, Surrozen and Bristol Myers Squibb. His institution has received grant support from Gilead, Salix, Tobira, Bristol Myers, Shire, Intercept, Merck, Astra Zeneca, Malinckrodt, Cumberland and Novartis. He receives royalties from Elsevier and UptoDate. Remaining authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal research (ethics)"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate (ethics)"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish (ethics)"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Plant reproducibility"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical Trials Registration"}}]}}